Dr. Tanya Borsuk is the President of North49 LLC Consulting, a boutique consulting firm focused on Business Development and Strategy for Early- through Late-Stage Biotechs. With over 17 years of experience in Buy and Sell-Side Business Development, VC/Equity Investments, Platform and Pipeline Innovation, Business Insights, and Corporate Strategy across the Global Biotech and Pharmaceutical communities, Dr. Borsuk has worked to drive effective company start-ups and drug discovery across numerous technology platforms (ex: AI/ML, Molecular Dynamics, Kinases/Small Molecules, mAbs, Cell Therapies) and Therapeutic Areas.

Her previous roles include CBO/Head of BD at Congruence Therapeutics and Sitryx Therapeutics, Vice President of Pipeline Strategy and Alliances at Flagship Pioneering, co-founder and Director of the Search and Evaluation and Hematology & Cell Therapy Business Development teams at Celgene Corporation and Bristol Myers Squibb, head of Global Market Insights at Celgene, and U.S Business Insights for Halaven at Eisai Pharmaceuticals. She began her career in Management Consulting at Easton Associates LLC, a boutique strategic management consulting firm focused on the Biotech and Pharma industries based in New York City.

Tanya holds a Doctorate in Cell Biology and Molecular Genetics from Rutgers University in New Jersey, a bachelor’s degree in Biology from Queen’s University at Kingston, Ontario, Canada, and a Mini-MBA from the Rutgers University Business School.